Article: MicroRNAs: Potential diagnostic markers and therapeutic targets for EBV-associated nasopharyngeal carcinoma

File Download Links for fulltext
(May Require Subscription)
Supplementary
  • Basic View
  • Metadata View
  • XML View
TitleMicroRNAs: Potential diagnostic markers and therapeutic targets for EBV-associated nasopharyngeal carcinoma
AuthorsHe, ML1
Luo, MXM1
Lin, MC1
Kung, HF1
Issue Date2012
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/bbaroco
CitationBiochimica Et Biophysica Acta - Reviews On Cancer, 2012, v. 1825 n. 1, p. 1-10 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.bbcan.2011.09.001
AbstractNasopharyngeal carcinoma (NPC) is a highly malignant cancer with local invasion and early distant metastasis. NPC is highly prevalent in the Southern China and South-eastern Asia. The genetic susceptibility, endemic environment factors, and Epstein-Barr virus (EBV) infection are believed to be the major etiologic factors of NPC. Once metastasis occurs, the prognosis is very poor. It is urgently needed to develop biomarkers for early clinical diagnosis/prognosis, and novel effective therapies for nasopharyngeal carcinoma. In this paper, we systematically reviewed the current progress of miRNA studies in NPC. It has been shown that both host encoded miRNAs and EBV encoded miRNAs play key roles in almost all the steps of epithelia cell carcinogenesis, including epithelial-mesenchymal to stem-like transition, cell growth, migration, invasion, and tumorigenesis. More importantly, some miRNAs could be secreted out and play a role in the microenvironments. The level of sera miRNAs is correlated with the copy numbers of host miRNAs in tumor biopsies. Promising results of gene therapy have been also achieved by lentiviral delivered miRNAs. Taken together, cell free miRNAs would be potential biomarkers of early clinical diagnosis/prognosis; while some miRNAs could be further developed into therapeutic agents in the future. © 2011 Elsevier B.V.
ISSN0304-419X
2011 Impact Factor: 9.38
2011 SCImago Journal Rankings: 1.407
DOIhttp://dx.doi.org/10.1016/j.bbcan.2011.09.001
ReferencesReferences in Scopus
DC Field
Value
dc.contributor.authorHe, ML
dc.contributor.authorLuo, MXM
dc.contributor.authorLin, MC
dc.contributor.authorKung, HF
dc.date.accessioned2012-10-08T03:20:54Z
dc.date.available2012-10-08T03:20:54Z
dc.date.issued2012
dc.description.abstractNasopharyngeal carcinoma (NPC) is a highly malignant cancer with local invasion and early distant metastasis. NPC is highly prevalent in the Southern China and South-eastern Asia. The genetic susceptibility, endemic environment factors, and Epstein-Barr virus (EBV) infection are believed to be the major etiologic factors of NPC. Once metastasis occurs, the prognosis is very poor. It is urgently needed to develop biomarkers for early clinical diagnosis/prognosis, and novel effective therapies for nasopharyngeal carcinoma. In this paper, we systematically reviewed the current progress of miRNA studies in NPC. It has been shown that both host encoded miRNAs and EBV encoded miRNAs play key roles in almost all the steps of epithelia cell carcinogenesis, including epithelial-mesenchymal to stem-like transition, cell growth, migration, invasion, and tumorigenesis. More importantly, some miRNAs could be secreted out and play a role in the microenvironments. The level of sera miRNAs is correlated with the copy numbers of host miRNAs in tumor biopsies. Promising results of gene therapy have been also achieved by lentiviral delivered miRNAs. Taken together, cell free miRNAs would be potential biomarkers of early clinical diagnosis/prognosis; while some miRNAs could be further developed into therapeutic agents in the future. © 2011 Elsevier B.V.
dc.description.natureLink_to_subscribed_fulltext
dc.identifier.citationBiochimica Et Biophysica Acta - Reviews On Cancer, 2012, v. 1825 n. 1, p. 1-10 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.bbcan.2011.09.001
dc.identifier.citeulike9857921
dc.identifier.doihttp://dx.doi.org/10.1016/j.bbcan.2011.09.001
dc.identifier.epage10
dc.identifier.issn0304-419X
2011 Impact Factor: 9.38
2011 SCImago Journal Rankings: 1.407
dc.identifier.issue1
dc.identifier.pmid21958739
dc.identifier.scopuseid_2-s2.0-80053537922
dc.identifier.spage1
dc.identifier.urihttp://hdl.handle.net/10722/168571
dc.identifier.volume1825
dc.languageeng
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/bbaroco
dc.publisher.placeNetherlands
dc.relation.ispartofBiochimica et Biophysica Acta - Reviews on Cancer
dc.relation.referencesReferences in Scopus
dc.subject.meshGene Therapy - Methods
dc.subject.meshHerpesvirus 4, Human - Genetics
dc.subject.meshHumans
dc.subject.meshMicrornas - Analysis
dc.subject.meshMolecular Targeted Therapy
dc.subject.meshNasopharyngeal Neoplasms - Diagnosis - Genetics - Therapy - Virology
dc.subject.meshPrognosis
dc.subject.meshRna, Viral - Analysis
dc.subject.meshTumor Markers, Biological - Analysis
dc.titleMicroRNAs: Potential diagnostic markers and therapeutic targets for EBV-associated nasopharyngeal carcinoma
dc.typeArticle
Author Affiliations
  1. Chinese University of Hong Kong